Shattuck Labs, Inc. - Common Stock (STTK)

Competitors to Shattuck Labs, Inc. - Common Stock (STTK)

Agenus Inc. 

Agenus Inc. is a biotechnology company focused on immuno-oncology. They develop therapies to activate the immune system to fight cancer, similar to Shattuck Labs. Both companies are exploring innovative drug candidates that leverage the immune system. However, Agenus has a more established product pipeline and collaborations, which gives them a competitive edge in terms of market presence and research funding.

Bluebird Bio, Inc. 

Bluebird Bio is known for its work in gene therapies focusing on genetic diseases and cancer. While their primary focus is on gene editing and making more of a genetic approach, they compete indirectly with Shattuck Labs in the oncology market. Bluebird has a more advanced pipeline and established partnerships, providing them with a significant advantage over Shattuck Labs in terms of funding and development opportunities.

Immunocore Holdings plc 

Immunocore is a biotechnology company specializing in T-cell engagers to treat cancer and other diseases. They compete with Shattuck Labs by leveraging similar technology aimed at immune system enhancement. However, Immunocore has made significant advancements in clinical development and partnerships with major pharmaceutical companies, thereby positioning itself as a leader in this area of biotechnology.

Macrogenics, Inc. 

Macrogenics, Inc. is engaged in the development of antibody-based therapeutics for the treatment of cancer. They compete with Shattuck Labs through their proprietary technology platforms that also target immune modulation. While both companies focus on cancer therapies, Macrogenics has substantial partnerships with larger pharmaceutical companies, granting them access to resources and infrastructure that Shattuck may lack at this stage.

Mirati Therapeutics, Inc.

Mirati Therapeutics focuses on genetic and epigenetic drivers of cancer, and although they are more genetic-targeted in their approach, they still overlap with Shattuck Labs in the oncology space. Mirati’s established clinical trials and recent successes in drug approvals give them a leverage in the competitive landscape of cancer therapies, placing them ahead of Shattuck Labs in terms of credibility and market share.